date:Aug 02, 2019
DSM has outlined favorable results in the first half-year of 2019. The Dutch multinational reported group sales up by 3 percent year-on-year and adjusted EBITDA up 12 percent (including 3 percent from IFRS 16). Total net profit for H1 2019 was 401 million, up versus the H1 2018 value of 633 million when correcting the temporary vitamin price effect of 275 million EBITDA, which followed an exceptional supply disruption in the industry. Adjusted Net Operating Free Cash Flow H1 2019 was 257 million